Clinical and molecular characteristics of 42 Danish patients with metastatic ALK fusion-positive lung cancer treated with first-line alectinib: A nationwide study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.First-line alectinib is effective for ALK-positive non-small cell lung cancer (NSCLC). Smoking significantly reduces time to treatment discontinuation, while baseline brain metastases do not impact alectinib efficacy in NSCLC patients.
Area Of Science
- Oncology
- Genetics
- Pharmacology
Background
- ALK-positive non-small cell lung cancer (NSCLC) is a distinct subtype.
- Targeted therapies like alectinib have improved outcomes.
- Predictors of treatment response and duration are crucial for optimizing therapy.
Purpose Of The Study
- To investigate if EML4-ALK fusions and ctDNA mutations predict time to treatment discontinuation (TTD) in first-line alectinib-treated ALK+ NSCLC patients.
- To evaluate clinical factors influencing TTD.
Main Methods
- A cohort of 42 treatment-naive, metastatic ALK+ NSCLC patients receiving first-line alectinib was analyzed.
- Plasma ctDNA was assessed using next-generation sequencing (NGS).
- Clinical data, including baseline brain metastases and smoking status, were collected.
Main Results
- Alectinib demonstrated efficacy irrespective of baseline brain metastases, EML4-ALK variant, or co-mutations.
- Median TTD for the cohort was 35.1 months.
- Smokers had a significantly shorter median TTD (11.2 months) compared to never-smokers (52.0 months).
Conclusions
- Alectinib is an effective first-line treatment for ALK+ NSCLC, even with brain metastases.
- EML4-ALK fusions are associated with smoking, which may negatively impact TTD.
- Larger studies are needed to confirm these findings and guide treatment strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.